BR112014012623A2 - métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico - Google Patents

métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico

Info

Publication number
BR112014012623A2
BR112014012623A2 BR112014012623A BR112014012623A BR112014012623A2 BR 112014012623 A2 BR112014012623 A2 BR 112014012623A2 BR 112014012623 A BR112014012623 A BR 112014012623A BR 112014012623 A BR112014012623 A BR 112014012623A BR 112014012623 A2 BR112014012623 A2 BR 112014012623A2
Authority
BR
Brazil
Prior art keywords
appropriateness
kit
enhancing
determining
composition
Prior art date
Application number
BR112014012623A
Other languages
English (en)
Inventor
D Plowman Gregory
Andres Herbert
Karl Johann
Wild Norbert
Elliott Rebecca
Lysbet De Hass Sanne
Scherer Stefan
Gloria Meng Yu-Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014012623A2 publication Critical patent/BR112014012623A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112014012623A 2011-12-05 2012-12-03 métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico BR112014012623A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11191922 2011-12-05
EP12171293 2012-06-08
PCT/EP2012/074184 WO2013083499A1 (en) 2011-12-05 2012-12-03 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112014012623A2 true BR112014012623A2 (pt) 2017-06-13

Family

ID=47501094

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012623A BR112014012623A2 (pt) 2011-12-05 2012-12-03 métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico

Country Status (15)

Country Link
US (1) US20140341893A1 (pt)
EP (1) EP2788769A1 (pt)
JP (1) JP2015502543A (pt)
KR (1) KR20140094594A (pt)
CN (1) CN104067128A (pt)
AR (1) AR089067A1 (pt)
AU (1) AU2012348600A1 (pt)
BR (1) BR112014012623A2 (pt)
CA (1) CA2854598A1 (pt)
IL (1) IL232656A0 (pt)
MX (1) MX2014006500A (pt)
RU (1) RU2014125520A (pt)
SG (1) SG11201402737SA (pt)
WO (1) WO2013083499A1 (pt)
ZA (1) ZA201403602B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082880A1 (en) * 2013-12-02 2015-06-11 Astrazeneca Ab Methods of selecting treatment regimens
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3018332A1 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
JP2019523404A (ja) * 2016-07-15 2019-08-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 全vegf−aのレベルを検出するための方法及び手段
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74201A0 (en) 1984-01-30 1985-04-30 Icrf Patents Limited Polypeptides for the detection and control of mammalian cell growth
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のneu関連タンパク質の検出及び定量
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2399129B1 (en) * 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
US8427093B2 (en) * 2010-07-02 2013-04-23 Woodward Hrt, Inc. Controller for actuation system employing Kalman estimator incorporating effect of system structural stiffness
WO2012010548A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
EP3156800A1 (en) * 2010-07-19 2017-04-19 F. Hoffmann-La Roche AG Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
AR089067A1 (es) 2014-07-30
US20140341893A1 (en) 2014-11-20
JP2015502543A (ja) 2015-01-22
EP2788769A1 (en) 2014-10-15
RU2014125520A (ru) 2016-02-10
SG11201402737SA (en) 2014-06-27
WO2013083499A1 (en) 2013-06-13
AU2012348600A1 (en) 2014-05-22
MX2014006500A (es) 2014-08-21
IL232656A0 (en) 2014-06-30
CN104067128A (zh) 2014-09-24
NZ624444A (en) 2016-07-29
KR20140094594A (ko) 2014-07-30
CA2854598A1 (en) 2013-06-13
ZA201403602B (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BR112014012623A2 (pt) métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
HUE054621T2 (hu) Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik
BR112013029226A2 (pt) método de cimentação e fluído curável
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
IL232510A0 (en) Treatment methods using an antibody against gamma interferon
BR112014006419A2 (pt) métodos para tratar um paciente com câncer, kit e artigo
BR112015005436A2 (pt) kit de tratamento, dispositivo de tratamento e método para fabricar um dispositivo
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
BR112013022766A2 (pt) método de administração de d-pirfenidona e kit
SG11201504791VA (en) Pharmaceutical composition for treating headache, and preparation method thereof
HK1214961A1 (zh) 粘多醣病 型的鞘內注射治療的方法和組合物
EP2995309A4 (en) COMPOSITION FOR LIPOLYSIS WITH PHOSPHATIDYLCHOLIN AND METHOD OF MANUFACTURING THEREOF
EP2709614A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
BR112013022306A2 (pt) método, e, composição
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
EP2856172A4 (en) COMPOSITIONS AND METHODS FOR TESTING THROMBOCYTE REACTIVITY AND TREATMENT SELECTION
BR112014012759A2 (pt) composto, composição e método para tratamento
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BR112013019224A2 (pt) composição, e metodo
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
UA117455C2 (uk) Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора
BR112014009421A2 (pt) combinação terapêutica e método para tratamento

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]